285 related articles for article (PubMed ID: 25656918)
1. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Nirogi R; Palacharla RC; Mohammed AR; Manoharan A; Ponnamaneni RK; Bhyrapuneni G
Chem Biol Interact; 2015 Mar; 230():9-20. PubMed ID: 25656918
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
Sridar C; Kenaan C; Hollenberg PF
Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.
Polasek TM; Elliot DJ; Somogyi AA; Gillam EM; Lewis BC; Miners JO
Br J Clin Pharmacol; 2006 May; 61(5):570-84. PubMed ID: 16669850
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
[TBL] [Abstract][Full Text] [Related]
7. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline.
Sharma U; Roberts ES; Hollenberg PF
Drug Metab Dispos; 1996 Jun; 24(6):669-75. PubMed ID: 8781784
[TBL] [Abstract][Full Text] [Related]
10. Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims.
Palacharla RC; Nirogi R; Uthukam V; Manoharan A; Ponnamaneni RK; Kalaikadhiban I
Xenobiotica; 2018 Jul; 48(7):663-675. PubMed ID: 28737446
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
12. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
Richter T; Schwab M; Eichelbaum M; Zanger UM
Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
[TBL] [Abstract][Full Text] [Related]
14. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
Fowler CJ; Mantle TJ; Tipton KF
Biochem Pharmacol; 1982 Nov; 31(22):3555-61. PubMed ID: 6817759
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Coles R; Kharasch ED
Pharm Res; 2008 Jun; 25(6):1405-11. PubMed ID: 18219560
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
17. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline.
Todd KG; Baker GB
J Affect Disord; 1995 Dec; 35(3):125-9. PubMed ID: 8749840
[TBL] [Abstract][Full Text] [Related]
18. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053
[TBL] [Abstract][Full Text] [Related]
19. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
Court MH; Almutairi FE; Greenblatt DJ; Hazarika S; Sheng H; Klein K; Zanger UM; Bourgea J; Patten CJ; Kwara A
Antimicrob Agents Chemother; 2014 Jul; 58(7):4145-52. PubMed ID: 24820076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]